Predictors of Outcome in Patients with Advanced Nonseminomatous Germ Cell Testicular Tumors
Authors:
- Tarkan YetisyigitTYTarkan Yetisyigit
- Nalan BabacanNBNalan Babacan
- Yuksel UrunYUYuksel Urun
- Erdogan Selcuk SeberESErdogan Selcuk Seber
- Sener CihanSCSener Cihan
- Erkan ArpaciEAErkan Arpaci
- Nuriye YildirimNYNuriye Yildirim
- Sercan AksoySASercan Aksoy
- Burcin BudakogluBBBurcin Budakoglu
- Nurullah ZenginNZNurullah Zengin
- Berna OksuzogluBOBerna Oksuzoglu
- Banu Cicek YalcinBYBanu Cicek Yalcin
Open Access
- 30 January 2014
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (2) , 831-835
Abstract
Predictor factors determining complete response to treatment are still not clearly defined. We aimed to evaluate clinicopathological features, risk factors, treatment responses, and survival analysis of patient with advanced nonseminomatous GCTs (NSGCTs). Between November 1999 and September 2011, 140 patients with stage II and III NSGCTs were referred to our institutions and 125 patients with complete clinical data were included in this retrospective study. Four cycles of BEP regimen were applied as a first-line treatment. Salvage chemotherapy and/or high-dose chemotherapy (HDCT) with autologous stem cell transplantation were given in patients who progressed after BEP chemotherapy. Post-chemotherapy surgery was performed in selected patients with incomplete radiographic response and normal tumor markers. The median age was 28 years. For the good, intermediate and poor risk groups, compete response rates (CRR) were, 84.6%, 67.9% and 59.4%, respectively. Extragonadal tumors, stage 3 disease, intermediate and poor risk factors, rete testis invasion were associated with worse outcomes. There were 32 patients (25.6%) with non-CR who were treated with salvage treatment. Thirty-one patients died from GCTs and 94% of them had stage III disease. Even though response rates are high, some patients with GCTs still need salvage treatment and cure cannot be achieved. Non-complete response to platinium-based first-line treatment is a negative prognostic factor. Our study confirmed the need for a prognostic and predictive model and more effective salvage approaches.Keywords
This publication has 29 references indexed in Scilit:
- Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancerAnnals of Oncology, 2012
- A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)Annals of Oncology, 2010
- Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised TrialEuropean Urology, 2007
- Outcome of patients with stage II and III nonseminomatous germ cell tumors: Results of a single centerIndian Journal of Cancer, 2007
- Prognostic variables for response and outcome in patients with extragonadal germ-cell tumorsAnnals of Oncology, 2002
- Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative GroupBritish Journal of Cancer, 1998
- Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.Journal of Clinical Oncology, 1997
- Recent Cancer Trends in the United StatesJNCI: Journal of the National Cancer Institute, 1995
- Prognostic factors in advanced nonseminomatous testicular cancer a multivariate logistic regression analysisCancer, 1988
- Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular CancerAnnals of Internal Medicine, 1977